ArticleCureus2024
Challenges in the Management of Severe Serotonin Syndrome: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serotonin syndrome (SS) is a potentially life-threatening condition that can result from excessive serotonergic activity, often due to SSRIs, formally known as selective serotonin reuptake inhibitors. The syndrome and its effects are often secondary to drug-drug interactions or dose-related. This case highlights a 47-year-old female who presents with a history of major depressive disorder, generalized anxiety disorder, and severe alcohol use disorder. She was brought to the Emergency Department after attempting suicide by ingesting an inordinate amount of bupropion (Wellbutrin). Although bupropion is not a direct serotonergic reuptake inhibitor, its inhibition of the CYP2D6 pathway has the potential to elevate the levels of alternative serotonergic agents, potentially leading to SS. The patient's symptoms were inclusive of autonomic instability and clonus, which are consistent with this syndrome, and which necessitated the discontinuation of all serotonergic medications, in addition to the initiation of supportive care. Management included benzodiazepines, guanfacine, and gabapentin to mitigate the glutamatergic activity SS can induce. This case emphasizes the need to closely monitor those prescribed this class of medications, while concomitantly incorporating interdisciplinary collaborative management for those afflicted with SS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.